Review Article
Hidden Nutritional Risks of Rapid Weight Loss: A Clinical and Nutraceutical Framework for Prevention in Pharmacological and Surgical Obesity Treatments
Bellani D*, Desai A, Anand S, Maldahiar SP, Mishra S and Hegde R
Department of Medical Affairs, IntelliMed Healthcare Solutions Sakhi House 2nd Floor, Corporate Park, VN Purav Marg, Swastik Chamber, Chembur, Mumbai, Maharashtra, India
*Corresponding author:Depti Bellani, Department of Medical Affairs, IntelliMed Healthcare Solutions Sakhi House 2nd Floor, Corporate Park, VN Purav Marg, Swastik Chamber, Chembur, Mumbai, Maharashtra India. E-mail Id: depti.bellani@intellimed.org
Article Information:Submission: 09/04/2026; Accepted: 24/04/2026; Published: 28/04/2026
Copyright: ©2026 Bellani D, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Obesity management has rapidly expanded with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual incretin therapies, alongside established bariatric surgery. Although these interventions induce durable weight loss, emerging evidence indicates, rapid weight reduction carries nutritional and metabolic consequences inadequately addressed in current clinical frameworks.
Objective: To synthesize existing evidence on the mechanisms, prevalence, and clinical impact of nutritional deficiencies associated with GLP-1–based therapies and bariatric surgery, and to propose an integrated, evidence-based approach to nutritional monitoring and supplementation.
Methods: This narrative review integrates data from randomized controlled trials, meta-analyses, observational studies, and international guidelines, including those from the American Diabetes Association (ADA), Endocrine Society, American Heart Association/American College of Cardiology/The Obesity Society (AHA/ACC/TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), British Obesity and Metabolic Surgery Society (BOMSS), and Indian Council of Medical Research (ICMR).
Results: Pharmacologic and surgical weight-loss modalities converge on pathways of reduced intake, altered gastrointestinal physiology, and systemic metabolic adaptation, resulting in a high protein and micronutrient deficiency risk. Evidence demonstrates that one-fourth of weight loss may derive from fat free mass, with clinically significant deficiencies emerging within the first year of therapy. While bariatric care incorporates structured nutritional surveillance and supplementation, pharmacologic pathways lack comparable protocols despite achieving similar magnitudes of weight loss. This gap is particularly relevant in Indian populations, where high baseline prevalence of micronutrient deficiency and distinct body composition profiles amplify vulnerability.
Conclusion: Rapid weight loss should be reframed as a state of heightened nutritional risk requiring proactive, structured management. Bariatric-style monitoring, individualized supplementation, and body composition assessment must be integrated into GLP-1–based care pathways to preserve metabolic benefits while preventing nutritional compromise. Future research should prioritize trials evaluating supplementation strategies and long-term nutritional outcomes in treated populations.
Objective: To synthesize existing evidence on the mechanisms, prevalence, and clinical impact of nutritional deficiencies associated with GLP-1–based therapies and bariatric surgery, and to propose an integrated, evidence-based approach to nutritional monitoring and supplementation.
Methods: This narrative review integrates data from randomized controlled trials, meta-analyses, observational studies, and international guidelines, including those from the American Diabetes Association (ADA), Endocrine Society, American Heart Association/American College of Cardiology/The Obesity Society (AHA/ACC/TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), British Obesity and Metabolic Surgery Society (BOMSS), and Indian Council of Medical Research (ICMR).
Results: Pharmacologic and surgical weight-loss modalities converge on pathways of reduced intake, altered gastrointestinal physiology, and systemic metabolic adaptation, resulting in a high protein and micronutrient deficiency risk. Evidence demonstrates that one-fourth of weight loss may derive from fat free mass, with clinically significant deficiencies emerging within the first year of therapy. While bariatric care incorporates structured nutritional surveillance and supplementation, pharmacologic pathways lack comparable protocols despite achieving similar magnitudes of weight loss. This gap is particularly relevant in Indian populations, where high baseline prevalence of micronutrient deficiency and distinct body composition profiles amplify vulnerability.
Conclusion: Rapid weight loss should be reframed as a state of heightened nutritional risk requiring proactive, structured management. Bariatric-style monitoring, individualized supplementation, and body composition assessment must be integrated into GLP-1–based care pathways to preserve metabolic benefits while preventing nutritional compromise. Future research should prioritize trials evaluating supplementation strategies and long-term nutritional outcomes in treated populations.
Keywords:GLP-1 receptor agonists; Dual incretin therapy; Bariatric surgery; Rapid weight loss; Nutritional deficiency; Sarcopenia